Keyphrases
12-month Outcomes
100%
Additional Treatment
100%
Anterior Segment
11%
Avascular Retina
11%
Bevacizumab
100%
Clinical Management
11%
Corrected Age
22%
Data-driven Analysis
11%
Diopter
11%
Dose Escalation
22%
Dose Level
11%
Fellow Eye
22%
High Risk
11%
Initial Dose
11%
Initial Treatment
11%
Intravitreal Bevacizumab
88%
Laser Therapy
11%
Non-associated
11%
Optic Atrophy
11%
Prematurely Born Infants
11%
Prophylactic Laser
11%
Refraction
11%
Refractive Error
11%
Retinopathy of Prematurity
100%
Short-term Treatment
11%
Strabismus
11%
Structural Results
22%
Treatment-related
11%
Ultra-low Dose
100%
Medicine and Dentistry
Bevacizumab
100%
Clinical Management
11%
Low Drug Dose
100%
Low Level Laser Therapy
11%
Optic Nerve Atrophy
11%
Refractive Error
11%
Retinopathy of Prematurity
100%
Retinopathy of Prematurity Treatment
22%
Short Course Therapy
11%
Strabismus
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Optic Nerve Atrophy
11%
Refraction Error
11%
Retrolental Fibroplasia
100%
Strabismus
11%